Literature DB >> 25075250

Epithelial and stromal expression of miRNAs during prostate cancer progression.

Qinghu Ren1, Jiaqian Liang2, Jianjun Wei3, Olca Basturk1, Jinhua Wang4, Garrett Daniels1, Lan Lin Gellert1, Yirong Li1, Ying Shen1, Iman Osman5, Jun Zhao6, Jonathan Melamed1, Peng Lee7.   

Abstract

Global microRNA (miRNA) profile may predict prostate cancer (PCa) behaviors. In this study, we examined global miRNA expression by miRNA profiling as well as specific miRNA expression levels in PCa epithelium and stroma by in situ hybridization (ISH) and correlated with various clinicopathological features. We first performed comprehensive miRNA profiling on 27 macrodissected cases of PCa by miRNA microarray. A total of 299 miRNAs were significantly dysregulated in high grade and advanced stage PCa. We demonstrated that PCa can be readily classified into high grade/stage and low-grade/stage groups by its global miRNA expression profile. Next, we examined the expression of several selected dysregulated miRNAs, including let-7c, miR-21, miR-27a, miR-30c, and miR-219, in PCa by ISH. The levels of miRNA expression in epithelial and stromal cells were scored semiquantitatively and compared with clinicopathological features, including age, race, Gleason score, stage, PSA recurrence, metastasis, hormone resistance and survival. We found that the expression of miR-30c and miR-219 were significantly down-regulated in PCa. miR-21 and miR-30c were significantly down-regulated in PCa in African Americans compared to Caucasian Americans. In addition, down-regulation of let-7c, miR-21, miR-30c, and miR-219 are associated with metastatic disease. Furthermore, down-regulation of miR-30c and let-7c are significantly associated with androgen-dependent PCa. In PCa stromal cells, let-7c downregulation is significantly associated with extraprostatic extension. Our data suggest that selected miRNAs may serve as potential biomarkers to predict cancer progression.

Entities:  

Keywords:  miRNA; prostate cancer progression

Year:  2014        PMID: 25075250      PMCID: PMC4113495     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  29 in total

Review 1.  Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.

Authors:  L Bubendorf; A Nocito; H Moch; G Sauter
Journal:  J Pathol       Date:  2001-09       Impact factor: 7.996

2.  Developmental regulation of microRNA expression in Schwann cells.

Authors:  Nolan G Gokey; Rajini Srinivasan; Camila Lopez-Anido; Courtney Krueger; John Svaren
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

3.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

4.  MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin.

Authors:  Tao Liu; Hua Tang; Yuanyuan Lang; Min Liu; Xin Li
Journal:  Cancer Lett       Date:  2008-09-13       Impact factor: 8.679

5.  Widespread deregulation of microRNA expression in human prostate cancer.

Authors:  M Ozen; C J Creighton; M Ozdemir; M Ittmann
Journal:  Oncogene       Date:  2007-09-24       Impact factor: 9.867

6.  Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors:  Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

7.  microRNA modulation of circadian-clock period and entrainment.

Authors:  Hai-Ying M Cheng; Joseph W Papp; Olga Varlamova; Heather Dziema; Brandon Russell; John P Curfman; Takanobu Nakazawa; Kimiko Shimizu; Hitoshi Okamura; Soren Impey; Karl Obrietan
Journal:  Neuron       Date:  2007-06-07       Impact factor: 17.173

8.  Expression of microRNAs associated with Gleason grading system in prostate cancer: miR-182-5p is a useful marker for high grade prostate cancer.

Authors:  Katsuki Tsuchiyama; Hideaki Ito; Minekatsu Taga; Seiji Naganuma; Yukinosuke Oshinoya; Ken-Ichi Nagano; Osamu Yokoyama; Hiroshi Itoh
Journal:  Prostate       Date:  2012-11-26       Impact factor: 4.104

9.  MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells.

Authors:  Tao Li; Dong Li; Jianjun Sha; Peng Sun; Yiran Huang
Journal:  Biochem Biophys Res Commun       Date:  2009-03-18       Impact factor: 3.575

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  29 in total

1.  miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

2.  microRNAs and DICER1 are regulated by 1,25-dihydroxyvitamin D in prostate stroma.

Authors:  Shweta Dambal; Angeline A Giangreco; Andres M Acosta; Andrew Fairchild; Zachary Richards; Ryan Deaton; Dennis Wagner; Reinhold Vieth; Peter H Gann; Andre Kajdacsy-Balla; Theodorus Van der Kwast; Larisa Nonn
Journal:  J Steroid Biochem Mol Biol       Date:  2017-01-12       Impact factor: 4.292

Review 3.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  Cansu Karakas; Cassie Wang; Fangming Deng; Hongying Huang; Dongwen Wang; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

4.  MiR-21/miR-375 ratio is an independent prognostic factor in patients with laryngeal squamous cell carcinoma.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun; Rui-Lin Li; Jun-Li Duan
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

5.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

Review 6.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

7.  MiR-217 promotes cutaneous squamous cell carcinoma progression by targeting PTRF.

Authors:  Ming Bai; Mingzi Zhang; Fei Long; Nanze Yu; Ang Zeng; Xiaojun Wang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

8.  Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.

Authors:  Darina Kachakova; Atanaska Mitkova; Elenko Popov; Ivan Popov; Alexandrina Vlahova; Tihomir Dikov; Svetlana Christova; Vanio Mitev; Chavdar Slavov; Radka Kaneva
Journal:  DNA Cell Biol       Date:  2014-12-18       Impact factor: 3.311

9.  Diagnostic and prognostic values of tissue hsa-miR-30c and hsa-miR-203 in prostate carcinoma.

Authors:  Ziling Huang; Long Zhang; Xianghua Yi; Xiaoting Yu
Journal:  Tumour Biol       Date:  2015-10-24

10.  microRNAs and Prostate Cancer.

Authors:  Sajni Josson; Leland W K Chung; Murali Gururajan
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.